

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number  
**WO 01/85984 A1**

(51) International Patent Classification<sup>7</sup>: C12Q 1/34, 1/37

(21) International Application Number: PCT/US01/14797

(22) International Filing Date: 8 May 2001 (08.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/567,283 8 May 2000 (08.05.2000) US  
09/702,068 30 October 2000 (30.10.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:  
US 09/702,068 (CIP)  
Filed on 30 October 2000 (30.10.2000)  
US 09/567,283 (CIP)  
Filed on 8 May 2000 (08.05.2000)

(71) Applicant (for all designated States except US):  
DAVISCO INTERNATIONAL FOODS, INC. [US/US];  
Suite 210, 11000 West 78th Street, Eden Prairie, MN  
55344 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DAVIS, Martin, E.  
[US/US]; 415 Lakeview Avenue, Tonka Bay, MN 55331  
(US). RAO, Anand [US/US]; 5057 Edgewater Court,  
Savage, MN 55378 (US). GAUTHIER, Sylvie [CA/CA];

7330 des Mesanges, Charny, Quebec G6X 3P8 (CA).  
POULIOT, Yves [CA/CA]; 7330 des Mesanges, Charny,  
Quebec G6X 3P8 (CA). GOURLEY, Line [CA/CA];  
1014 2nd Avenue, Quebec, Quebec G1L 3C3 (CA).  
ALLAIN, Ann, Françoise [CA/CA]; 1750, rue du Pont,  
Saint-Lambert de Lauzon, Quebec G0S 2W0 (CA).

(74) Agent: CARVIS, Thaddius, J.; Ware, Fressola, Van der  
Shuys & Adolphson LLP, Bradford Green, Building Five,  
755 Main Street, P.O. Box 224, Monroe, CT 06468 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/85984 A1

(54) Title: ENZYMATIC TREATMENT OF WHEY PROTEINS FOR THE PRODUCTION OF ANTIHYPERTENSIVE PEPTIDES, THE RESULTING PRODUCTS AND TREATMENT OF HYPERTENSION IN MAMMALS

(57) Abstract: Enzymatic digests of whey protein concentrates were prepared using animal, bacterial and fungal proteases, and evaluated for antihypertensive activities. ACE-inhibitory activity and antihypertension activity were obtained with a hydrolysate of whey protein isolate prepared with a porcine trypsin.

## DESCRIPTION

Enzymatic Treatment Of Whey Proteins For The Production  
Of Antihypertensive Peptides, The Resulting Products And  
Treatment Of Hypertension In Mammals

## Background of The Invention

The invention in one aspect relates to a method for suppressing angiotensin-converting enzyme (ACE), a composition effective for this purpose and a method for preparing the composition, specifically by enzymatic conversion of whey proteins.

In another aspect, the invention relates to a method for reducing hypertension in mammals with specific hydrolysates obtained by the enzymatic conversion of whey proteins.

Hypertension has been reported to be the most important cause of human deaths in industrialized countries. (See, for example, Laragh, J. H., 1979. *L'hypertension. Recherche*, 105 (10): 1068-1076.) Nearly 30% of the fatalities among adults would result from hypertension or from its renal, coronary or neurological complications. The elucidation of the physiological mechanisms responsible for hypertension has lead the pharmaceutical industry to propose angiotensin converting enzyme (ACE) -inhibitory substances. ACE catalyses the degradation of angiotensin I into angiotensin II, a strong vasoconstrictor.

Peptides found in Brazilian snake venom have been identified as the most effective natural substance for the inhibition of ACE. (See, Ferreira, S. H., Bartelt, D. C., Greene, L. J., 1970. Isolation of bradykinin-potentiating peptides from *Bothrops jararaca* venom. *Biochemistry*, 9 (13): 2583-2593.) The inhibitory effect of natural peptides has been related to their binding at the active site of ACE. (See, Maubois, J. L., Léonil, J., Trouvé, R., Bouhallab, S., 1991. Les peptides du lait à activité physiologique III. Peptides du lait à effet cardiovasculaire: activités antithrombotique et antihypertensive. *Lait*, 71: 249-255.)

A structure-function study of these various bioactive peptides has suggested that they often possess a Pro-Pro, Ala-Pro or Ala-Hyp at their C-terminal sequence. (See, Maruyama, S., Suzuki, H., 1982. A peptide inhibitor of angiotensin I converting enzyme in the tryptic hydrolysate of casein. *Agric. Biol. Chem.*, 46 (5): 1393-1394; and Oshima, G., Shimabukuro, H., Nagasawa, K. 1979. Peptide inhibitors of angiotensin I-converting enzyme in digests of gelatin by bacterial collagenase. *Biochim. Biophys. Acta*, 566: 128-137.) The occurrence of proline might also contribute to the ACE-inhibitory activity of peptides derived from food proteins. (See, Kohmura, M., Nio, N., Kubo, K., Minoshima, Y., Munekata, E., Ariyoshi, Y. 1989. Inhibition of angiotensin-converting enzyme by synthetic peptides of human  $\beta$ -casein. *Agric. Biol. Chem.*, 53 (8): 2107-2114.)

Maruyama and Suzuki [*supra*] have evidenced such amino acid sequences in peptides from tryptic casein hydrolysates. The authors have shown that the peptide f23-34 from  $\alpha_{s1}$  casein (bovine, variant B), possesses ACE-inhibitory activity estimated by an  $IC_{50}$  value (concentration needed to inhibit 50% ACE activity) of 77 $\mu$ M. Numerous other studies followed this work and revealed other ACE-inhibitory peptides in casein hydrolysates. In a recent review, Nakano has reported the occurrence of 18 distinct milk protein-derived peptide sequences, found in sour milk, and which have been shown to possess ACE-inhibitory activity. (Nakano, T., 1998, Milk derived peptides and hypertension reduction. *Int. Dairy J.*, 8: 375-381.)

However, only a few studies have reported the occurrence of ACE-inhibitory activities among whey proteins hydrolysates. Abubakar, *et al.*, have determined the ACE-inhibitory activity in whey protein hydrolysates using seven different enzymes: trypsin, proteinase-K, actinase-E, thermolysin, papain, pepsin and chymotrypsin. It was shown that the specificity of the enzyme had a pronounced effect on the resulting ACE-inhibitory activity of the hydrolysate, and that the biological activity was originating from the major whey proteins ( $\beta$ -lg,  $\alpha$ -la, BSA, Ig) and not from the caseinomacropptide. (Abubakar, A., Saito, T., Aimar, M. V., Itoh, T. 1996. New derivation of the inhibitory activity against angiotensin converting enzyme (ACE) from sweet cheese whey. *Tohoku J. Agric. Res.*, 47 (1-2): 1-8.) More recent work from Abubakar, *et al.*, has allowed the identification of nine peptide

sequences, namely  $\beta$ 2-microglobulin (f18-20),  $\beta$ -lactoglobulin (f78-80), serum albumin (f221-222),  $\beta$ -casein (f59-61, f59-64, f62-63, f80-90, f157-158, f205-206), among which  $\beta$ -lactoglobulin (f78-80) showed the strongest antihypertensive activity in spontaneously hypertensive rats. (Abubakar, A., Saito, T., Kitazawa, H., Kawai, Y., Itoh, T., 1998, 5 Structural analysis of new antihypertensive peptides derived from cheese whey protein by proteinase K digestion. *J. Dairy Sci.*, 12: 3131-3138.) Finally, Mullaly *et al.*, have demonstrated that a peptidic fraction, isolated by using RP-HPLC, from a tryptic hydrolysate prepared with bovine  $\beta$ -lactoglobulin had an  $IC_{50}$  value of 159.8  $\mu$ mol/L, compared to Captopril, a commercial drug commonly used in hypertension treatment, which has an  $IC_{50}$  10 of 0,006  $\mu$ mol/L. (Mullally, M. M., Meisel, H., FitzGerald, R. J., 1997. Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine  $\beta$ -lactoglobulin. *FEBS Letters*, 402: 99-101.) Mass spectrometry analyses have allowed the identification of peptide f142-148 from  $\beta$ -lactoglobulin as being responsible for the ACE-inhibitory activity in tryptic hydrolysates of  $\beta$ -lactoglobulin. The same peptidic 15 sequence obtained by chemical synthesis showed an  $IC_{50}$  of 42.6  $\mu$ mol/L.

It would be desirable to provide improvements in the field of suppressing angiotensin-converting enzyme (ACE) and to identify additional materials capable of treating hypertension or its symptoms, especially materials that can be easily employed as part of a 20 simple regimen such as being included in food items.

### Summary of the Invention

It is an object of the invention to provide improvements in the field of suppressing angiotensin-converting enzyme (ACE).

25 It is an object of the invention to provide a method for suppressing angiotensin-converting enzyme.

It is another object of the invention to provide a composition effective for suppressing angiotensin-converting enzyme.

5           It is yet another objective of the invention to provide a method for preparing a composition effective for suppressing angiotensin-converting enzyme, specifically by enzymatic conversion of whey proteins.

It is an object of the invention to provide improvements in the field of treating hypertension in mammals.

10

It is an object of the invention to provide a method for reducing heart rate and blood pressure associated with hypertension in mammals.

15           These and other objects are accomplished by one aspect of the invention, by improvements which enable the production of an ACE-suppressing composition by the hydrolysis of whey protein hydrolysate, the recovery of the ACE-suppressing composition, and a regimen for use of the ACE-suppressing composition.

20           The process for preparing the ACE-suppressing composition comprises: preparing an aqueous solution of whey protein isolate and a proteolytic enzyme; holding said solution under conditions effective to partially hydrolyze said whey protein isolate to provide a hydrolysate having increased ACE-suppressing activity in mammals; and recovering said hydrolysate from said solution. The proteolytic enzyme is inactivated as necessary, preferably by heating. The hydrolysate is preferably dried for use in a regimen which comprises oral  
25           administration to a mammal, such as a human or a domestic pet such as a dog or cat, in amounts and at intervals effective to suppress ACE-activity.

30           Other objects are accomplished by another aspect of the invention by a mammalian treatment regimen entailing orally administration to humans or other mammals effective amounts of a hypertension-reducing composition obtained by: preparing an aqueous solution of whey protein isolate and a proteolytic enzyme; holding said solution under conditions

effective to partially hydrolyze said whey protein isolate to provide a hydrolysate having the ability to reduce hypertension in mammals; and recovering said hydrolysate from said solution. The proteolytic enzyme is inactivated as necessary, preferably by heating. The hydrolysate is preferably dried for use in a regimen which comprises oral administration to  
5 a mammal, such as a human or a domestic pet such as a dog or cat, in amounts and at intervals effective to reduce hypertension in mammals. Many of the preferred aspects of the invention are described below.

Many of the preferred aspects of the invention are described below.

### Brief Description of the Drawings

Figures 1-4 summarize the results of laboratory testing for antihypertension treatment discussed in detail below.

10 **Figure 1.** Changes in heart rate (A) and mean arterial blood pressure (B) elicited by single oral administration (time 0) of vehicle (0.2 mM PBS pH 7.2; O, n=36 rats) or 601 at the dose of 30 (n=9 rats), 75 (n=8) or 150 mg/kg (n=7) in conscious, unrestrained spontaneously hypertensive rats (SHR). Each point indicates the mean with standard errors shown by vertical lines. \*P< 0.05 versus vehicle-treated group, ANOVA followed by  
15 Fisher's test. HR, heart rate; bpm, beats per minute; MAP, mean arterial blood pressure.

**Figure 2.** Changes in heart rate (A) and mean arterial blood pressure (B) elicited by single oral administration (time 0) of vehicle (0.2 mM PBS pH 7.2; O, n=36 rats) or 603K at the dose of 30 (n=10 rats), 75 (n=10) or 150 mg/kg (n=10) in conscious, unrestrained  
20 spontaneously hypertensive rats (SHR). Each point indicates the mean with standard errors shown by vertical lines. \*P< 0.05 versus vehicle-treated group, ANOVA followed by Fisher's test. HR, heart rate; bpm, beats per minute; MAP, mean arterial blood pressure.

**Figure 3.** Changes in heart rate (A) and mean arterial blood pressure (B) elicited by

single oral administration (time 0) of vehicle (0.2 mM PBS pH 7.2; O, n=36 rats) or 605K at the dose of 30 (n=8 rats), 75 (n=8) or 150 mg/kg (n=8) in conscious, unrestrained spontaneously hypertensive rats (SHR). Each point indicates the mean with standard errors shown by vertical lines. HR, heart rate; bpm, beats per minute; MAP, mean arterial blood pressure.

**Figure 4.** Changes in heart rate (A) and mean arterial blood pressure (B) elicited by single oral administration (time 0) of vehicle (0.2 mM PBS pH 7.2; O, n=36 rats) or BiPRO at the dose of 30 (n=8 rats), 75 (n=8) or 150 mg/kg (n=8) in conscious, unrestrained spontaneously hypertensive rats (SHR). Each point indicates the mean with standard errors shown by vertical lines. HR, heart rate; bpm, beats per minute; MAP, mean arterial blood pressure.

#### Detailed Description of The Invention

Whey protein isolates (WPI) can be obtained from commercial-scale fractionation of cheese whey by various processes, including ion-exchange processing using cationic and/or anionic resins selected for the intended functionality of the isolate. (Pearce, R.J., 1992, Whey protein recovery and whey protein fractionation, *Whey and Lactose Processing*, JG Zadow, Ed., Elsevier, London, 271-316.) Commercial WPI products issued from ion-exchange processing, such as BiPRO™ (Davisco Foods International, Inc., LeSueur, MN), are characterized by a high protein content (>94% w/w), low ash content (<3%), traces (<1%) of fat and lactose. The protein distribution of a typical WPI shows 55-65%  $\beta$ -lactoglobulin, 17-25%  $\alpha$ -lactalbumin, 4-7% bovine serum albumin, 7-11% immunoglobulins and less than 1% others.

BiPRO™ whey protein isolate is the preferred source of whey protein isolate for use in the invention and is available from Davisco Foods International, Inc., with offices at 11000 W. 78th Street, Suite 210, Eden Prairie, Minnesota 55344. The preferred BiPRO™ whey protein isolate has a (PDCAAS) Protein Digestibility Corrected Amino Acid Score of 1.14. The fat and lactose levels are less than 1%. The BiPRO™ whey protein isolate is prepared

by ion-exchange technology, and contains about 55-65% (w/w)  $\beta$ -lactoglobulin. Preferably, the whey protein isolate employed according to the invention will contain at least 55% and preferably at least 60%  $\beta$ -lactoglobulin, with the remaining comprising  $\alpha$ -lactalbumin, serum albumin and immunoglobulins in the above ranges. *BiPRO*<sup>TM</sup> is essentially undenatured and is fully soluble over the pH range 2.0 to 9.0, and has the following analysis:

|    | Analysis*          | Specification | Typical Range  | Test Method      |
|----|--------------------|---------------|----------------|------------------|
|    | Moisture (%)       | 5.0 max.      | 4.9 $\pm$ 0.1  | Vacuum Oven      |
|    | Protein, dry basis | 95.0 min.     | 97.8 $\pm$ 0.4 | Combustion       |
| 10 | (N x 6.38)(%)      |               |                |                  |
|    | Fat (%)            | 1.0 max.      | 0.3 $\pm$ 0.1  | Mojonnier        |
|    | Ash (%)            | 3.0 max.      | 2.0 $\pm$ 0.3  | Gravimetric      |
|    | Lactose (%)        | 1.0 max.      | < 0.5          | by difference    |
|    | pH                 | 6.7 - 7.5     | 7.0 $\pm$ 0.1  | 10% Sol. @ 20°C. |

\* All results reported "AS IS" basis except where noted.  
Standard Methods for the Examination of Dairy Products, 16th Edition.

As noted, whey protein isolates other than *BiPRO*<sup>TM</sup> can be employed and where used preferably have similar analyses to that above, varying by from 0 to 25%, *e.g.*, from 5 to 10%, or less, from the above Typical Range values. A suitable whey protein isolate can be produced having similar properties through a selective ion exchange process that selects the primary functional proteins - beta-lactoglobulin and alpha-lactalbumin - for concentration and spray drying. Such a process is described in U. S. Patent No. 4,154,675 to Jowett, *et al.*, and U. S. Patent No. 4,218,490 to Phillips, *et al.* If properly produced, whey protein fractions having lower protein contents, *e.g.*, as low as 35%, might be employed. In addition,  $\beta$ -lg produced by ion exchange separation can also be employed, but is less preferred than the *BiPRO*<sup>TM</sup> whey protein isolate.

On a more detailed analysis of *BiPRO*<sup>TM</sup> whey protein isolate, the following is found for each 100 grams of whey protein isolate:



| Component |                         |     |
|-----------|-------------------------|-----|
|           | Calories                | 374 |
|           | Calories From Total Fat | 3   |
| 5         | Total Fat (g)           | 0.3 |
|           | Saturated Fat (g)       | 0.2 |
|           | Cholesterol (mg)        | 10  |
|           | Sodium (mg)             | 600 |
|           | Potassium (mg)          | 120 |
| 10        | Total Carbohydrates (g) | 0   |
|           | Dietary Fiber (g)       | 0   |
|           | Sugars (g)              | 0   |
|           | Protein (g)             | 93  |
|           | Vitamin A (IU)          | 20  |
| 15        | Vitamin C (mg)          | 2.0 |
|           | Calcium (mg)            | 120 |
|           | Iron (mg)               | 5   |
|           | Phosphorus (mg)         | 25  |
|           | Magnesium (mg)          | 15  |
| 20        | Ash (g)                 | 2   |
|           | Moisture (g)            | 5   |

And, to provide an amino acid profile of the preferred *BiPRO*<sup>TM</sup> whey protein isolate, samples were subjected to drying for 24 hours in a dessicator over phosphorus pentoxide and sodium hydroxide. The dry samples were hydrolyzed in HCl vapor (6N HCl with 1% phenol and 0.5% sodium sulfite) under Argon atmosphere. After 20 hours of hydrolysis at 110 degrees Celsius, the samples were dissolved in 200  $\mu$ l of Beckman Na-S sample buffer. This acid hydrolysis method destroys tryptophan.

Analyses were conducted on a Beckman 6300 Amino Acid Analyzer. Norleucine was used as an internal standard. The analysis showed the following:

| Grams Amino Acid Per |                  |               |              |
|----------------------|------------------|---------------|--------------|
|                      | Amino Acid       | 100g protein  | 100g powder  |
|                      | Alanine          | 7.6           | 7.01         |
| 5                    | Arginine         | 2.0           | 1.84         |
|                      | Aspartate        | 10.1          | 9.31         |
|                      | Cysteine/Cystine | 4.3           | 3.96         |
|                      | Glutamine        | 14.3          | 13.18        |
|                      | Histidine        | 1.6           | 1.48         |
| 10                   | Isoleucine *     | 5.4           | 4.98         |
|                      | Leucine *        | 13.7          | 12.63        |
|                      | Lysine *         | 9.6           | 8.85         |
|                      | Methionine *     | 2.4           | 2.21         |
|                      | Phenylalanine *  | 3.1           | 2.86         |
| 15                   | Proline          | 4.5           | 4.14         |
|                      | Serine           | 4.90          | 4.52         |
|                      | Threonine *      | 5.30          | 4.89         |
|                      | Tyrosine         | 2.90          | 2.67         |
|                      | Valine *         | 5.60          | 5.16         |
| 20                   | <b>Totals</b>    | <b>100.10</b> | <b>92.29</b> |

\* Essential Amino Acids

Again, when whey protein isolates other than *BiPRO*<sup>TM</sup> are employed, they preferably have similar analyses to that above, varying by from 0 to 25%, e.g., from 5 – 10%, or less, from the above values.

Enzymatic digests of *BiPRO*<sup>TM</sup> and of commercial  $\beta$ -lg-rich product were prepared using animal, bacterial and fungal proteases, in order to determine the potential of these commercial substrates for the preparation of peptide mixtures having antihypertensive

activities. The objective of the work was to determine the ACE-inhibitory activity of various hydrolysates generated by enzymatic hydrolysis from whey protein isolates obtained by ion-exchange chromatography, in comparison with other commercially-available whey protein hydrolysates.

5

#### MATERIALS AND METHODS FOR ACE INHIBITION

Whey protein hydrolysate WPH 917 (84.5% protein w/w) was obtained from New Zealand Milk Product Inc. (Santa Rosa, USA). Whey protein hydrolysate LE80GF (80.0% w/w) was obtained from DMV International (New-York, USA). Whey protein isolate (BiPRO™) and  $\beta$ -lactoglobulin-rich product were obtained from Davisco Foods International (Le Sueur, MN, USA). Purified peptidic sequence *Ala-Leu-Pro-Met-His-Ile-Arg* modelling the peptide f-142-148 from  $\beta$ -lg was chemically-synthesized by the *Service de séquence de peptides de l'Est du Québec* (Ste-Foy, Qc, Canada). HEPES Sodium salt, Hippuryl-L-Histidyl-L-Leucine, and Angiotensin Converting Enzyme (from rabbit lung) were purchased from Sigma Chemical Co. (St. Louis, USA). All other products used were analytical grade.

Whey proteins (BiPRO™ or  $\beta$ -lg) were solubilized at 20% W/V, adjusted to pH 8.0 or 8.5 by using a mixture of NaOH and KOH 4N and maintained at temperatures between 40°C and 50°C corresponding to the optimal temperature of the enzymes used. Table 1 reports the characteristics of the enzymes used for the preparation of the enzymatic hydrolysates for the study. BiPRO™ and  $\beta$ -lg-rich product were utilized for the preparation of 601 and 605, but only Bipro™ was used for 603K. The protein solutions were incubated with the proteases at an enzyme:substrate ratio of 1:800 for AS-601, 1:50 for AS-603K and 1:100 for AS-605K. The enzymatic hydrolysis was performed under pH-stat conditions until a degree of hydrolysis (DH) of 5.5-6.5% for AS-601 and under a combination of pH-stat and osmometry methods until a DH of 11.0-12.5% for AS-603K, and a DH of 19.5-20.5% for AS-605K. The hydrolysis reaction was stopped at the selected DH values by means of heat treatment (75 to 85°C for 15 s) in a plate heat exchanger to inactivate the enzyme and followed by cooling and storage at 5-10 °C until further processing. The resulting hydrolysates were further spray dried and handled as powdered ingredient. Fractions can be

taken based on molecular weight and tested for relative activity, with the most active fractions selected.

A typical analysis for the AS-601K and AS-603K products prepared from *BiPRO*<sup>TM</sup> whey protein hydrolysate are given below.

|    | Analysis* (AS-601K)                | Specification | Typical Range | Test Method      |
|----|------------------------------------|---------------|---------------|------------------|
|    | Moisture (%)                       | 5.0 max.      | 4.0 ± 0.5     | Vacuum Oven      |
|    | Total Nitrogen (TN), %             | 14.1 min.     |               | Combustion       |
| 10 | Protein dry basis<br>(N x 6.38)(%) | 90.0 min.     | 91.0 ± 0.5    | Calculated       |
|    | Amino Nitrogen (AN), %             | 1.7 min.      |               | Formol Titration |
|    | AN/TN, %                           | 12.0 min.     | 12.0 - 15.0   | Calculated       |
|    | Degree of Hydrolysis, %            | 5.0 min.      | 5.5 - 6.5     | OPA Method       |
| 15 | Fat (%)                            | 1.0 max       | < 1.0         | Mojonnier        |
|    | Ash (%)                            | 6.0 max.      | 5.5 ± 0.3     | Standard **      |
|    | Lactose (%)                        | 1.0 max.      | < 1.0         | by difference    |
|    | pH                                 | 8.5 max.      | 8.0 ± 0.2     | 10% Sol. @ 20°C  |

20

| Molecular Weight Profile (HPLC) Range (Daltons) | Soluble Peptides*** |
|---|---------------------|
| > 5000  | 50 - 55%            |
| 2000 - 5000                                     | 15 - 20%            |
| < 2000  | 30 - 35%            |

- 25 \* All results reported "AS IS" basis except where noted.  
 \*\* Standard Methods for the Examination of Dairy Products, 16th Edition.  
 \*\*\* Percent of total soluble peptides in 0.45 µ filtrate.

| Analysis*(AS-603K)              | Specification   | Typical Range | Test Method         |
|---------------------------------|-----------------|---------------|---------------------|
| Moisture (%)                    | 5.0 max.        | 4.0 ± 0.5     | Vacuum Oven         |
| Total Nitrogen (TN), %          | 14.1 min.       |               | Combustion          |
| Protein, dry basis (N x 6.38) % | 94.0 min.       | 95.0 ± 0.5    | Calculated          |
| Amino Nitrogen (AN), %          | 2.2 min.        | 2.4 ± 0.2     | Formol<br>Titration |
| AN/TN, %                        | 15.8 min.       | 16.3 ± 0.5    | Calculated          |
| Degree of Hydrolysis, %         | 7.7 min.        | 8.7 ± 1.0     | OPA Method          |
| Fat (%)                         | 1.0 max.        | <1.0          | Mojonnier           |
| Ash (%)                         | 5.0 max.        | 3.5 ± 0.3     | Gravimetric         |
| Lactose (%)                     | 1.0 max.        | <1.0          | by difference       |
| pH                              | 7.5 max.        | 7.0 ± 0.2     | 10% Sol. @<br>20°C. |
| Scorched Particles              | 15 mg/25 g max. | 7.5 mg        | ADPI                |

5

**Molecular Weight Profile****(HPLC)**

| Range (Daltons) | Peptides |
|-----------------|----------|
| >10,000         | 30 – 35% |
| 5000 – 10,000   | 10 – 15% |
| 2000 – 5000     | 25 – 30% |
| <2000           | 25 – 30% |

Table 1 Characteristics of the enzyme sources used for the preparation of hydrolysates

| Enzyme<br>(Name, Supplier)  | Source    | Optimal<br>pH | Temp.<br>(°C) | Hydrolysate                            |
|---|-----------|---------------|---------------|--|
| Trypsin VI<br>Trypsin Activity 2,400 U/mg<br>minimum<br>Chymotrypsin activity 350 U/mg<br>minimum<br><i>Canadian Innovatech Inc</i><br><i>Abbotsford, BC, Canada</i>                              | Porcine   | 8.0           | 37            | AS-601 (BiPRO™)<br><br>AS-601 (β-1g)   |
| Protease P Amano-6<br>Proteinase activity 60,000 units/g<br>minimum<br><i>Amano, Enzyme Co. Ltd</i><br><i>Rochester, IL, USA</i>  | Fungal    | 7.5           | 45            | AS-605K (BiPRO™)<br><br>AS-605K (β-1g) |
| Multifect<br>Activity 3,000 GSU/ml<br>minimum (Note: GSU is<br>Genencor Subtlisin Units ---<br>developed internally by<br>Genencor)<br><i>Genencor International</i><br><i>Rochester, NY, USA</i> | Bacterial | 8.5           | 50            | AS-603K (BiPRO™)                       |

## 5 Determination of ACE-inhibitory activity

The ACE-inhibitory activity was measured *in vitro* by a spectrophotometric assay according to the method of Cushman and Cheung. (Cushman, D.N., Cheung, H.S. 1971 Spectrophotometric assay and properties of the angiotensin converting enzyme of rabbit lung.

- 10 Biochemical Pharmacology, 20: 1637-1648.) According to this method, hippuric acid is liberated from hippuryl-L-histidyl-L-leucine (HHL) by the enzymatic reaction of ACE. After extraction by ethyl acetate and removal of ethyl acetate by heat evaporation, hippuric acid is dissolved in deionized water.

Table 2 summarizes the experimental conditions used for the assay. Absorbance of the hippuric acid solution at 228 nm was determined by spectrophotometry.

**Table 2** Assay conditions for the measurement of ACE-inhibitory activity

| Reagent volumes (μl)                                | Sample | Control | Blank |
|---|--------|---------|-------|
| Substrate solution <sup>1</sup>                     | 200    | 200     | 200   |
| Sample solution <sup>2</sup>                        | 50     | —       | —     |
| HEPES-HCl Buffer <sup>3</sup>                       | —      | 50      | 50    |
| Deionized water                                     | 20     | 20      | 20    |
| mixed using vortex and equilibrated to 37°C         |        |         |       |
| Stopping solution <sup>4</sup>                      | —      | —       | 300   |
| ACE solution <sup>5</sup>                           | 30     | 30      | 30    |
| mixed using vortex and incubated at 37°C for 20 min |        |         |       |
| Stopping solution                                   | 300    | 300     | —     |
| Total volume (μl)                                   | 600    | 600     | 600   |

1: HHL was dissolved in HEPES-HCl Buffer to obtain a final concentration of 0.3% (w/v).

2: Samples were diluted at the appropriate concentration with HEPES-HCl Buffer.

3: HEPES Sodium Salt (50 mM) with 300 mM NaCl, pH adjusted at 8.3 with 1M HCl

4: 1M HCl.

10 5: ACE from rabbit lung dissolved in HEPES-HCl at a final concentration of 0.33 unit ml<sup>-1</sup>.

Inhibitory activity was calculated according to the following equation:

$$\text{Inhibitory activity (\%)} = [(A_{\text{control}} - A_{\text{sample}}) / (A_{\text{control}} - A_{\text{blank}})] \times 100 \quad [1]$$

15

where A represents absorbance. A plot of the inhibitory activity (%) versus log<sub>10</sub> of sample concentration (mg powder ml<sup>-1</sup>) was generated using 6 different concentrations of samples for BiPRO™, AS-601 (BiPRO™β-Ig), commercial hydrolysates (WPH 917, LE80GF) and of synthetic peptide (f142-148) from β-Ig. Each concentration was tested in triplicate and the

mean value was plotted in the curves. The  $IC_{50}$  value (expressed in terms of mg powder  $ml^{-1}$ , defined as the concentration of inhibitor which gives 50% inhibition of ACE activity, was calculated using the linear regression equations of the curves.

- 5 The linear regression equations corresponding to all the hydrolysates under study are reported in Table 3. The data show that non-hydrolyzed *BiPRO*<sup>TM</sup> has very low ACE-inhibitory activity ( $IC_{50}$  380 mg powder.  $ml^{-1}$ ) in comparison with all other products under study. The highest ACE-inhibitory activity was obtained with synthetic peptide f142-148 of  $\beta$ -lg for which 50% of inhibition was already obtained at the lowest concentration ( $IC_{50}$  0.04 mg powder. $ml^{-1}$ ). The ACE-inhibitory effectiveness of the hydrolysates under study followed  
10 the order : AS-603K (*BiPRO*<sup>TM</sup>) > AS-605K (*BiPRO*<sup>TM</sup>) > AS-601 (*BiPRO*<sup>TM</sup>) > AS-605K ( $\beta$ -lg) > AS-601 ( $\beta$ -lg) > LE80GF > WPH 917.

- Table 3, as follows presents the linear regression equations ( $y = m \ln X + b$ ) of the ACE-inhibitory activity curves obtained with synthetic peptide  $\beta$ -lg (f142-148), in  
15 comparison with the hydrolysates under study.

Table 3

| Sample                                 | Slope<br><i>m</i> | Y-intercept<br><i>b</i> | Reg. Coeff.<br>$R^2$ |
|--|-------------------|-------------------------|----------------------|
| $\beta$ -lg f142-148                   | 10.35             | 84.4                    | .83                  |
| AS-601 ( <i>BiPRO</i> <sup>TM</sup> )  | 15.39             | 62.4                    | .99                  |
| AS-605 ( <i>BiPRO</i> <sup>TM</sup> )  | 14.76             | 63.0                    | .99                  |
| AS-603K ( <i>BiPRO</i> <sup>TM</sup> ) | 14.33             | 67.9                    | .96                  |
| AS-601 ( $\beta$ -lg)                  | 17.69             | 51.9                    | .98                  |
| AS-605 ( $\beta$ -lg)                  | 16.98             | 60.7                    | .98                  |
| WPH 917 (NZMP)                         | 19.40             | 44.8                    | .96                  |
| LE80GF (DMV)                           | 18.01             | 50.7                    | .97                  |

The values of  $IC_{50}$  calculated for all the samples under study are listed in Table 4. The samples of *BiPRO*<sup>TM</sup> showed lower ACE-inhibitory activity with an  $IC_{50}$  of 376 mg powder. $ml^{-1}$ ), whereas synthetic peptide f142-148 of  $\beta$ -lg showed the lowest value (0.04 mg



powder.ml<sup>-1</sup>). The hydrolysates derived from *BiPRO*<sup>TM</sup> or  $\beta$ -lg-rich products all gave lower IC<sub>50</sub> values (0.29 to 0.90 mg powder.ml<sup>-1</sup>) than the other commercial hydrolysates (0.96 and 1.30 mg powder.ml<sup>-1</sup>). Also the hydrolysates derived from *BiPRO*<sup>TM</sup> led to lower IC<sub>50</sub> values than those derived from the  $\beta$ -lg-rich product (ex. AS-601 *BiPRO*<sup>TM</sup>=0.45 vs AS-601 $\beta$ -lg= 0.90 mg powder.ml<sup>-1</sup>).

**Table 4** Values of IC<sub>50</sub> for various whey protein products

| Sample                                 | Description  | IC <sub>50</sub><br>(mg powder ml <sup>-1</sup> ) |
|--|--|---|
| <i>BiPRO</i> <sup>TM</sup>             | whey protein isolate                                     | 376.7   |
| AS-601 ( <i>BiPRO</i> <sup>TM</sup> )  | hydrolyzed <i>BiPRO</i> <sup>TM</sup>                    | 0.45  |
| AS-601 ( $\beta$ -lg)                  | hydrolyzed $\beta$ -lg                                   | 0.90  |
| AS-605 ( <i>BiPRO</i> <sup>TM</sup> )  | hydrolyzed <i>BiPRO</i> <sup>TM</sup> , Kosher certified | 0.42  |
| AS-605 ( $\beta$ -lg)                  | hydrolyzed $\beta$ -lg, Kosher certified                 | 0.53  |
| AS-603K ( <i>BiPRO</i> <sup>TM</sup> ) | Hydrolyzed <i>BiPRO</i> <sup>TM</sup> , Kosher certified | 0.29  |
| WPH 917 (NZMP)                         | whey protein hydrolysate                                 | 1.30  |
| LE80GF (DMV)                           | whey protein hydrolysate                                 | 0.96  |
| $\beta$ -lg f142-148                   | synthetic peptide  | 0.04  |

## DISCUSSION

10

Our observations show that the enzymatic hydrolysis of whey proteins issued from ion-exchange chromatography, such as *BiPRO*<sup>TM</sup> whey protein isolate generates hydrolysates having superior ACE-inhibitory activities, compared to commercial hydrolysates prepared with other sources of whey proteins. Moreover, it appears that *BiPRO*<sup>TM</sup> whey protein isolate is a better substrate than  $\beta$ -lg-rich product for the preparation of hydrolysates with antihypertensive activity, as seen by the lower IC<sub>50</sub> values obtained (Table 4) for AS-601, AS-603K and 605K prepared from *BiPRO*<sup>TM</sup> whey protein isolate. This observation was unexpected since it was hypothesized that a  $\beta$ -lg-rich product would offer a higher potential for producing ACE-Inhibiting peptides, especially the fragment  $\beta$ -lg 142-148 liberated by

15

trypsin (Mullally, M. M., Meisel, H., FitzGerald, R. J., 1997. Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine  $\beta$ -lactoglobulin. *FEBS Letters*, 402: 99-101). In fact, the hydrolysates having the lowest  $IC_{50}$  (0.29 mg powder  $ml^{-1}$ ) were obtained by hydrolysis with bacterial protease (AS-603K) and not with trypsin (AS-601). Altogether, our results suggest the occurrence of a synergistic effect when *BiPRO*<sup>TM</sup> whey protein isolate is used as the substrate, but the explanation for this phenomenon is not clear.

*BiPRO*<sup>TM</sup> whey protein isolate and others similarly prepared are preferred for a composition with regard to principal protein composition ( $\beta$ -lg,  $\alpha$ -la, etc.), and content of minor proteins (lactoferrin, lactoperoxydase, immunoglobulins) or peptidic fragments (caseinomacropptides, proteoses peptones, etc.) which may be precursors of the production of peptides with very strong ACE-inhibition activity during enzymatic hydrolysis. Some of these minor proteins may be at a lower concentration in the  $\beta$ -lg-rich product, as a result of the different fractionation conditions.

Also, it must be emphasized that the enzymes used for the preparation of enzymatic hydrolysates from *BiPRO*<sup>TM</sup> whey protein isolate (601, 605K and 603K) respectively Trypsin VI, P Amano 6 and Multifect have very different specificities. Trypsin is known to cleave only the peptidic bonds in the vicinity of Arg and Lys, whereas the two other enzymes have a much broader specificity and will lead to a greater number of shorter peptides. The recent work from Abubakar, *et al.*, *supra*, suggests that short molecules such as tri- and even di-peptides can have an antihypertensive effect. It is clear that the fragments 142-148 and 78-80 of  $\beta$ -lg are not the only ACE-inhibitors responsible for the antihypertensive properties of all whey protein hydrolysates.

The synergistic effect on ACE-inhibitory potential of whey protein hydrolysates when *BiPRO*<sup>TM</sup> whey protein isolate is used may also be originating from its low mineral content, especially with regards to divalent cations such as calcium (15-20 meq/kg) or magnesium (<1 meq/kg). These physicochemical conditions may prevent the occurrence of *peptide-peptide*

interactions and therefore preserve the high ACE-inhibitory potential of the hydrolysate. This hypothesis will be further investigated by comparing the mineral composition of *BiPRO*<sup>TM</sup> whey protein isolate with that of  $\beta$ -lg-rich product which showed a lower ACE-inhibitory potential.

5

This study has shown that the enzymatic hydrolysis of *BiPRO*<sup>TM</sup> leads to a synergistic effect in terms of ACE-inhibitory potential of the hydrolysates obtained. It appears that the synergy could result from unique compositional characteristics brought by the ion-exchange process in relation with the presence of minor proteins or fragments.

10

#### MATERIALS AND METHODS FOR TREATMENT OF HYPETENSION IN MAMMALS

Enzymatic digests of *BiPRO*<sup>TM</sup> whey protein isolate were prepared using animal, bacterial and fungal proteases, in order to determine the potential of these commercial  
15 substrates for the preparation of peptide mixtures having antihypertensive activities. The main objective of the present study was to investigate the antihypertensive effect of some specific whey protein hydrolysates. The following summarizes experiments that have been carried out in conscious spontaneously hypertensive rats (SHR) to characterize the antihypertensive effect and establish the dose response curve for each hydrolysate. The SHR  
20 are considered as a genetic model of essential hypertension and are currently used to understand the development and establishment of hypertension and to determine the blood pressure lowering effect of newly synthesized antihypertensive drugs. Moreover, in a previous study carried out in SHR, we found that the intravenous injection of an angiotensin I-converting enzyme (ACE) inhibitor, Captopril, caused a marked reduction in blood pressure  
25 accompanied by significant vasodilations in renal, superior mesenteric and hindquarter vascular beds (unpublished data). Therefore, the SHR appears to be very reactive to ACE inhibition and then should provide us with very useful information in determining if specific whey protein hydrolysates exhibit a significant antihypertensive property.

30

Three whey protein hydrolysates (namely, 601, 603K and 605K) and controls phosphate buffered saline (PBS) and untreated *BiPRO* whey protein isolate, have been

examined. The effects of each whey protein on mean and phasic arterial blood pressure and heart rate have been investigated in conscious unrestrained male SHR. In the present study, the animals were chronically instrumented with one intravascular catheter implanted in the left femoral artery to permit a continuous recording of blood pressure and heart rate. This technique is very well developed in our laboratory and is routinely performed (Bachelard, H. and G. Drolet, Cardiovascular responses to paraventricular (PVN) injections of opioid agonists in conscious rats, *Abstract Society for Neuroscience*. 18: 1175, 1992; Bachelard, H. and M. Pitre, Regional haemodynamic effects of  $\mu$ -,  $\delta$ -,  $\kappa$ -opioid agonists microinjected into the hypothalamic paraventricular nuclei of conscious, unrestrained rats, *Br. J. Pharmacol*, 115: 613-621, 1995; Pitre, M., H. Gaudreault, M. Santure, A. Nadeau, and H. Bachelard. Isradipine and insulin sensitivity in hypertensive rats, *Am. J. Physiol.*, 39: E1038-E1048, 1999; Pitre, M., A. Nadeau and H. Bachelard, Insulin sensitivity and hemodynamic responses to insulin in Wistar-Kyoto and spontaneously hypertensive rats, *Am. J. Physiol.* 271: E658-E668, 1996). This experimental approach constitutes a powerful tool to investigate the hemodynamic responses to whey proteins in conscious rats. The non-invasive technique currently used by others to measure systolic blood pressure, the tail cuff sphygmomanometer, is stressful for the animal, (the rat has to be immobilized in a restrainer during measurement), and is subject to a large variability. Therefore, considering the inherent variability in blood pressure measurements in conscious animals, and that the SHR rats are known to be very reactive to stressful stimuli, we believed that there is some uncertainty in measurements made with the tail cuff technique, particularly in establishing a steady baseline measurement. In contrast, by directly and continuously recording blood pressure, it is easier to take into account this variability and make more reliable blood pressure measurements. Moreover, our rats were well adapted to the system for a few days prior to the experiments, and direct measurement of blood pressure was made without causing any pain or stress to the animal. Therefore, the direct and continuous recording of blood pressure and heart rate in conscious, unrestrained animals represent a clear advantage over the other non-invasive technique.

Whey protein isolate (BiPRO™) was obtained from Davisco Foods International (Le Sueur, MN, USA). HEPES Sodium salt, Hippuryl-L-Histidyl-L-Leucine, and Angiotensin

Converting Enzyme (from rabbit lung) were purchased from Sigma Chemical Co. (St. Louis, USA). All other products used were analytical grade.

Whey proteins (*BiPRO*<sup>TM</sup>) were solubilized at 20% W/V, adjusted to pH 8.0 or 8.5 by using a mixture of NaOH and KOH 4N and maintained at temperatures between 40°C and 50°C corresponding to the optimal temperature of the enzymes used. Table 1 reports the characteristics of the enzymes used for the preparation of the enzymatic hydrolysates for the study. *BiPRO*<sup>TM</sup> whey protein isolate was utilized for the preparation of 601, 603K and 605K. The protein solutions were incubated with the proteases at an enzyme:substrate ratio of 1:800 for 601, 1:50 for 603K and 1:100 for 605K. The enzymatic hydrolysis was performed under pH-stat conditions until a degree of hydrolysis (DH) of 4.5-6.5% for 601 and under a combination of pH-stat and osmometry methods until a DH of 7.0-10.0% for 603K, and a DH of 13.0-17.0% for 605K. The hydrolysis reaction was stopped at the selected DH values by means of heat treatment (75 to 85°C for 15 s) in a plate heat exchanger to inactivate the enzyme and followed by cooling and storage at 5-10 °C until further processing. The resulting hydrolysates were further spray dried and handled as powdered ingredient. Fractions can be taken based on molecular weight and tested for relative activity, with the most active fractions selected.

A typical analysis for the 601K and 603K products prepared from *BiPRO*<sup>TM</sup> whey protein hydrolysate are given below.

|    | Analysis* (601)                    | Specification | Typical Range | Test Method      |
|----|------------------------------------|---------------|---------------|------------------|
|    | Moisture (%)                       | 5.0 max.      | 4.0 ± 0.5     | Vacuum Oven      |
|    | Total Nitrogen (TN), %             | 14.1 min.     |               | Combustion       |
| 25 | Protein dry basis<br>(N x 6.38)(%) | 90.0 min.     | 91.0 ± 0.5    | Calculated       |
|    | Amino Nitrogen (AN), %             | 1.7 min.      |               | Formol Titration |
|    | AN/TN                              | 12.0 min.     | 12.0 - 15.0   | Calculated       |
|    | Degree of Hydrolysis, %            | 5.0 min.      | 5.5 - 6.5     | OPA Method       |
| 30 | Fat (%)                            | 1.0 max       | < 1.0         | Mojonnier        |
|    | Ash (%)                            | 6.0 max.      | 5.5 ± 0.3     | Standard **      |

|             |          |           |                 |
|-------------|----------|-----------|-----------------|
| Lactose (%) | 1.0 max. | < 1.0     | by difference   |
| pH          | 8.5 max. | 8.0 ± 0.2 | 10% Sol. @ 20°C |

5

### Molecular Weight Profile (HPLC) Range (Daltons) Soluble Peptides\*\*\*

|                |          |
|----------------|----------|
| > 10,000       | 50 - 60% |
| 5,000 - 10,000 | 10 - 20% |
| 2000 - 5000    | 10 - 20% |
| < 2000         | 10 - 20% |

10

\* All results reported "AS IS" basis except where noted.

\*\* Standard Methods for the Examination of Dairy Products, 16th Edition.

\*\*\* Percent of total soluble peptides in 0.45 µ filtrate.

15

| Analysis*( 603K)                | Specification      | Typical Range | Test Method         |
|---------------------------------|--------------------|---------------|---------------------|
| Moisture (%)                    | 5.0 max.           | 4.0 ± 0.5     | Vacuum Oven         |
| Total Nitrogen (TN), %          | 14.1 min.          |               | Combustion          |
| Protein, dry basis (N x 6.38) % | 94.0 min.          | 95.0 ± 0.5    | Calculated          |
| Amino Nitrogen (AN), %          | 2.2 min.           | 2.4 ± 0.2     | Formol<br>Titration |
| AN/TN, %                        | 15.8 min.          | 16.3 ± 0.5    | Calculated          |
| Degree of Hydrolysis, %         | 7.0 min.           | 7-10          | OPA Method          |
| Fat (%)                         | 1.0 max.           | <1.0          | Mojonnier           |
| Ash (%)                         | 5.0 max.           | 3.5 ± 0.3     | Gravimetric         |
| Lactose (%)                     | 1.0 max.           | <1.0          | by difference       |
| pH                              | 7.5 max.           | 7.0 ± 0.2     | 10% Sol. @<br>20°C. |
| Scorched Particles              | 15 mg/25 g<br>max. | 7.5 mg        | ADPI                |

### Molecular Weight Profile (HPLC)

Range (Daltons)  
>10,000

Peptides  
25 - 35%

|               |          |
|---------------|----------|
| 5000 – 10,000 | 10 – 20% |
| 2000 – 5000   | 25 – 35% |
| <2000         | 20 – 30% |

The above hydrolysates are characterized by a degree of hydrolysis of from 4.5% to 10.0%. This is determined by OPA Methodology.

5 Table 1 Characteristics of the enzyme sources used for the preparation of hydrolysates

| Enzyme<br>(Name, Supplier)  | Source    | Optimal<br>pH | Temp.<br>(°C) | Hydrolysate |
|---|-----------|---------------|---------------|-------------|
| Trypsin VI<br>Trypsin Activity 2,400 U/mg<br>minimum<br>Chymotrypsin activity 350 U/mg<br>minimum<br><i>Canadian Innovatech Inc</i><br><i>Abbotsford, BC, Canada</i>                              | Porcine   | 8.0           | 37            | 601         |
| Protease P Amano-6<br>Proteinase activity 60,000 units/g<br>minimum<br><i>Amano, Enzyme Co. Ltd</i><br><i>Lombard, IL, USA</i>  | Fungal    | 7.5           | 45            | 605K        |
| Multifect<br>Activity 3,000 GSU/ml<br>minimum (Note: GSU is<br>Genencor Subtlisin Units ---<br>developed internally by<br>Genencor)<br><i>Genencor International</i><br><i>Rochester, NY, USA</i> | Bacterial | 8.5           | 50            | 603K        |

### Determination of antihypertension activity -- Methods

All surgical and experimental procedures followed institutional animal care guidelines. Male SHR rats (aged 20 to 24 weeks and weighing 300-350 g) were purchased from Charles River Canada. The rats were anesthetized with a mixture of ketamine-xylazine (100 and 10 mg kg<sup>-1</sup>), respectively, i.p., supplemented as required) and one catheter was implanted in the distal abdominal aorta via the left femoral artery (for measurement of blood pressure and heart rate). Then, the catheter was tunneled subcutaneously to emerge at the back of the neck and was passed through a flexible, protecting spring attached to a custom-made harness worn by the rat. The rats were given s.c. injections of Ampicillin (150 mg kg<sup>-1</sup>) and Anafen (5mg kg<sup>-1</sup>) and returned to their home cages. Experiments began at least 4 days after this surgical step.

Throughout the experiments, three variables were recorded (heart rate and phasic and mean arterial blood pressure) using a Biopac Data Acquisition and Analysis system (Model MP 100, AcqKnowledge software version 3.1). At selected time points heart rate, phasic and mean arterial blood pressure were measured, to represent the full profile of the effects of the hydrolysates or *BiPRO* whey protein isolate, and related to the pre-treatment baseline value. The rats were conscious, unrestrained and were allowed free access to water and food for the duration of the experiment.

### Experimental protocol

The cardiovascular changes elicited by oral administration of *BiPRO* whey protein isolate or specific whey protein hydrolysates (601, 603K, 605K) have been evaluated in conscious, unrestrained SHR. The rats were used on four consecutive days, during which they received increasing doses of only one specific hydrolysate (601, 603K, 605K) or the *BiPRO* by gastric intubation. The lyophilized whey protein hydrolysate powder was dissolved in 0.2 mM PBS (pH 7.2) (the same vehicle, 0.2 mM PBS, was used for control administrations) and was given in a volume of 0.5 ml. All solutions were freshly prepared. Thus, on a typical day, soon after basal measurements of blood pressure and heart rate, the



rats were given the vehicle (control PBS on day 1) or an isolated dose of a specific hydrolysate (30 mg/kg on day 2, 75 mg/kg on day 3 and 150 mg/kg on day 4) or *BiPRO* whey protein isolate (30 mg/kg on day 2, 75 mg/kg on day 3 and 150 mg/kg on day 4). The blood pressure and heart rate effects of a single oral administration of PBS, *BiPRO* whey protein isolate or the whey protein hydrolysate was evaluated over a period of 7 hours.

## Results

Resting values for cardiovascular variables measured every morning before any intervention during four consecutive days are shown in Table 2. As we can see, there was no significant difference between the basal mean arterial blood pressure and heart rate values measured on days 1, 2, 3 and 4.

**Table 2. Baseline values of heart rate (HR) and mean arterial blood pressure (MAP) in conscious, unrestrained SHR rats.**

| Treatment                                | Weight, g | Age, Week  | Day | HR (bpm) | MAP(mmHg) |
|--|-----------|------------|-----|----------|-----------|
| Vehicle (PBS)<br>N=36                    | 322 ± 4   | 24.1 ± 0.2 | 1   | 311 ± 6  | 173 ± 3   |
| #601 (30 mg/kg <sup>-1</sup> )<br>N=9    | 321 ± 9   | 23.2 ± 0.5 | 2   | 308 ± 8  | 174 ± 6   |
| #601 (75 mg/kg <sup>-1</sup> )<br>N=8    | 317 ± 9   | 23.4 ± 0.6 | 3   | 320 ± 13 | 179 ± 4   |
| #601 (150 mg/kg <sup>-1</sup> )<br>N=7   | 313 ± 10  | 23.0 ± 0.5 | 4   | 305 ± 19 | 175 ± 9   |
| #603K (30 mg/kg <sup>-1</sup> )<br>N=10  | 315 ± 7   | 23.7 ± 0.2 | 2   | 301 ± 10 | 168 ± 7   |
| #603K (75 mg/kg <sup>-1</sup> )<br>N=10  | 315 ± 7   | 23.7 ± 0.2 | 3   | 304 ± 9  | 167 ± 5   |
| #603K (150 mg/kg <sup>-1</sup> )<br>N=10 | 315 ± 7   | 23.7 ± 0.2 | 4   | 292 ± 11 | 164 ± 5   |
| #605K (30 mg/kg <sup>-1</sup> )<br>N=8   | 321 ± 6   | 24.0 ± 0.0 | 2   | 290 ± 9  | 170 ± 5   |

|    |   |         |            |   |          |         |
|----|---|---------|------------|---|----------|---------|
|    | #605K (75 mg/kg <sup>-1</sup> )<br>N=8  | 321 ± 6 | 24.0 ± 0.0 | 3 | 296 ± 14 | 176 ± 9 |
| 5  | #605K (150 mg/kg <sup>-1</sup> )<br>N=8 | 321 ± 6 | 24.0 ± 0.0 | 4 | 299 ± 13 | 163 ± 6 |
|    | BiPRO (30 mg/kg <sup>-1</sup> )<br>N=8  | 328 ± 5 | 25.5 ± 0.2 | 2 | 299 ± 9  | 182 ± 5 |
| 10 | BiPRO (75 mg/kg <sup>-1</sup> )<br>N=8  | 328 ± 5 | 25.5 ± 0.2 | 3 | 300 ± 11 | 179 ± 6 |
| 15 | BiPRO (150 mg/kg <sup>-1</sup> )<br>N=8 | 328 ± 5 | 25.5 ± 0.2 | 4 | 290 ± 6  | 168 ± 7 |

Values are means ± SEM; *n* is the number of rats. (Groups represent those used to assess blood pressure and heart rate effects of single oral administration of vehicle (PBS), 601, 603K, 605K or BiPRO whey protein isolate in conscious, unrestrained SHR. MAP, mean arterial blood pressure; HR, heart rate; bpm, beats per minute.

### Cardiovascular responses to hydrolysate 601

Figure 1 shows the changes in heart rate and mean arterial blood pressure after oral administration of 0.5 ml of 0.2 mM PBS (*n*=36) or hydrolysate 601 at doses of 30 (*n*=9), 75 (*n*=8) or 150 mg/kg (*n*=7) in conscious, unrestrained spontaneously hypertensive rats (SHR). Each point indicates the mean with standard errors shown by vertical lines. \**P* < 0.05 versus vehicle-treated group, ANOVA followed by Fisher's test. HR, heart rate; bpm, beats per minute; MAP, mean arterial blood pressure. Except for the 75 mg/kg dose, which elicited a significant (at 4, 6 and 7 h) decrease in heart rate (maximum of -77 ± 14 bpm at 6 h), we found no significant difference between the heart rate responses elicited by intra-gastric administration of PBS and hydrolysate 601 at the doses of 30 and 150 mg/kg. However, we observed a significant reduction in mean arterial blood pressure following intra-gastric administration of the different doses of hydrolysate 601 when compared to control administration of PBS.

Thus, at the dose of 30 mg/kg we observed a significant hypotensive effect ( $-27 \pm 6$  mm Hg) 6 hours after administration of the hydrolysate. At the dose of 75 mg/kg of hydrolysate we observed a marked and long-lasting hypotensive effect (significant at 1-7 h) when compared with the effects of control administration of PBS. The maximum decrease in mean arterial blood pressure ( $-39 \pm 6$  mm Hg) was achieved 6 h after the administration. A similar hypotensive effect was also observed following the intra-gastric administration of 150 mg/kg of the hydrolysate (significant at 1 and 3-7 h). The maximum decrease in mean arterial blood pressure ( $-32 \pm 7$  mm Hg) was achieved 6 h after the administration.

#### 10 Cardiovascular responses to BiPRO and hydrolysate 603K, 605K

Figures 2-4 show the changes in heart rate and mean arterial blood pressure after oral administration of 0.5 ml of 0.2 mM PBS (n=36) or hydrolysate 603K (figures 2) or 605K (figure 3) or BiPRO whey protein isolate (figure 4) at doses of 30, 75, or 150 mg/kg. We found no significant difference between the heart rate or mean arterial blood pressure responses elicited by intra-gastric administration of PBS and hydrolysate 603K or 605K or BiPRO whey protein isolate at the different doses tested.

#### Conclusions

20.

The present results indicate that:

-Single oral administration of hydrolysate 601 (at the doses of 75 or 150 mg/kg) in conscious unrestrained SHR significantly reduced mean arterial blood pressure from 1 to 7 hours after administration.

25

-Blood pressure returned to the initial level at 24 hours after administration.

-Conversely, the hydrolysate 603K and 605K and the control BiPRO whey protein isolate (at any of the doses tested) did not change the mean arterial blood pressure of the SHR rats in this study.

30

A suitable regimen for treatment with the noted hydrolysate 601 will comprise oral administration of the above doses of 75 to 150 mg/kg at intervals of from 2 to 24 hours. More broadly, the dosages and intervals could be increased or decreased by from 50 to 500 percent, as might be indicated by treatment over time.

5

The above description is intended to enable the person skilled in the art to practice the invention. It is not intended to detail all of the possible modifications and variations which will become apparent to the skilled worker upon reading the description. It is intended, however, that all such modifications and variations be included within the scope of the invention which is seen in the above description and otherwise defined by the following claims. The claims are meant to cover the indicated elements and steps in any arrangement or sequence which is effective to meet the objectives intended for the invention, unless the context specifically indicates the contrary.

10

## CLAIMS

1. A process for preparing an ACE-suppressing composition comprising:
  - 5 preparing an aqueous solution of whey protein isolate and a proteolytic enzyme;
  - holding said solution under conditions effective to partially hydrolyze said whey protein isolate to provide a hydrolysate having increased ACE-suppressing activity in mammals; and
  - recovering said hydrolysate from said solution.
- 10 2. A process according to claim 1 wherein the proteolytic enzyme is inactivated.
3. A process according to claim 1 wherein the proteolytic enzyme is inactivated by heating following hydrolysis.
- 15 4. A process according to claim 1 wherein the hydrolysate is dried.
5. A whey protein hydrolysate as prepared according to claim 1.
6. A treatment for a mammal to suppress ACE, said regimen comprising:
  - 20 orally administering to the mammal, a product prepared according to claim 1 in amounts and at intervals effective to suppress ACE-activity.
7. A treatment regimen for a mammal to reduce symptoms of hypertension, said regimen comprising:
  - 25 orally administering to the mammal, a whey protein hydrolysate prepared by treatment of a whey protein isolate as described, in amounts and at intervals effective to reduce symptoms of hypertension.
8. A treatment according to claim 7, wherein the hydrolysate is prepared from a whey protein isolate characterized as follows:
  - 30

|   | Analysis           | Specification | Typical Range  |
|---|--------------------|---------------|----------------|
|   | Moisture (%)       | 5.0 max.      | $4.7 \pm 0.2$  |
|   | Protein, dry basis | 95.0 min.     | $97.5 \pm 1.0$ |
| 5 | (N x 6.38)(%)      |               |                |
|   | Fat (%)            | 1.0 max.      | $0.6 \pm 0.2$  |
|   | Ash (%)            | 3.0 max.      | $1.7 \pm 0.3$  |
|   | Lactose (%)        | 1.0 max.      | < 0.5          |
|   | pH                 | 6.7 - 7.5     | $7.0 \pm 0.2$  |

10

9. A treatment according to claim 8 wherein the enzyme employed in the hydrolysis comprises trypsin.

10. A treatment according to claim 9 wherein the enzyme employed in the hydrolysis comprises trypsin from mammal, poultry or fish sources.

11. A treatment according to claim 9 wherein the enzyme employed in the hydrolysis comprises porcine trypsin.

12. A treatment according to any of claims 7-11, wherein the hydrolysate is characterized by molecular weight profiles (HPLC) within the ranges (Daltons)

|  |                | soluble peptides*** |
|--|----------------|---------------------|
|  | > 10,000       | 50 - 60%            |
|  | 5,000 - 10,000 | 10 - 20%            |
|  | 2000 - 5000    | 10 - 20%            |
|  | < 2000         | 10 - 20%            |

25

\*\*\* Percent of total soluble peptides in 0.45  $\mu$  filtrate.

13. A treatment according to any of claims 7-12, wherein the hydrolysate is characterized by a degree of hydrolysis of from 3 to 20%.

30

14. A treatment according to any of claims 7-1, wherein the hydrolysate will be orally administered at a dose of 75 to 150 mg/kg at intervals of from 2 to 24 hours.

Fig. 1




Fig. 2






Fig. 3





Fig. 4



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/14797

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC(7) : C12Q 1/34, 1/37<br>US CL : 435/18,23,24<br>According to International Patent Classification (IPC) or to both national classification and IPC   |  |   |   |  |
|---|--|---|---|--|
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>U.S. : 435/18,23,24<br>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>WEST  |  |   |   |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |  |   |   |  |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.   |   |  |
| Y   | Database Derwent on WEST, AN 1995-070230. 'Blood pressure inhibitory composition useful for preventing hypertension - includes potassium and caseino:glycopeptide'. JP 06345664 A. 20 December 1994, see abstract.   | 1-12, 14  |   |  |
| Y   | Database Derwent on WEST, AN 1992-392238. 'New ACE inhibiting peptide for hypertension treatment and health foods - contain peptide obtd. by trypsin decomposing whey protein'. JP 04282400 A 07 October 1992, see abstract.   | 1-12, 14  |   |  |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.  |  |   |   |  |
| <table border="0"> <tr> <td>           * Special categories of cited documents:<br/>           "A" document defining the general state of the art which is not considered to be of particular relevance<br/>           "E" earlier document published on or after the international filing date<br/>           "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br/>           "O" document referring to an oral disclosure, use, exhibition or other means<br/>           "P" document published prior to the international filing date but later than the priority date claimed         </td> <td>           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br/>           "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br/>           "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br/>           "Z" document member of the same patent family         </td> </tr> </table> |  |   | * Special categories of cited documents:<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier document published on or after the international filing date<br>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"Z" document member of the same patent family |
| * Special categories of cited documents:<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier document published on or after the international filing date<br>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed   | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"Z" document member of the same patent family |   |   |  |
| Date of the actual completion of the international search<br>20 JULY 2001   |  | Date of mailing of the international search report<br>24 AUG 2001 |   |  |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230   |  | Authorized officer<br>ALTON PRYOR<br>Telephone No. (703) 308-1234 |   |  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/14797

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| Y         | Database Derwent on WEST, AN: 1992-392237. 'New angiotensin converting enzyme-inhibiting peptide - can be used in the treatment of hypertension or as health food'. JP 04282398 A, 07 October 1992, see abstract. | 1-12, 14              |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/14797

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☒ Claims Nos.: 13  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.